Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
August 22nd, 2022
Info GC
Let’s talk Pink Sheet stocks. And then a couple of good candidates. Including one that is actually one of the largest stocks in the world.
Pink sheets are listings for stocks that trade over the counter (OTC) rather than on a major U.S. stock exchange. Many pink sheet listings are stock shares in companies that cannot meet the requirements for listing on a major U.S. stock exchange like the New York Stock Exchange (NYSE).
Salient Points:
Check out Investopedia, so I don’t have to simply list stuff.
Examples:
Readen Holding Corp (OTC: RHCO) is a listed venture capital corporation with over 30 years of activity. The Company has a long history of engaging in the retail trade. More recently, it has been active in the Fintech, Online Payment and E-commerce industries, a vast potential growth sector es-North America. RHCO has subsidiaries and liaison offices in Europe, Asia and New Zealand.
Readen’s strengths are acquiring distressed assets, selling the weak parts, and growing the best assets. The free App is available in all the usual places. The Company is aggressively pursuing an uplisting to the OTCQB. It hopes to conclude this year.
RHCO reported an increase in Revenue of 634.42% compared to the quarter ending December 2021, which is also a year-over-year increase of 161.39%. After two previous quarters of a minor loss, the Company has recorded a nominal profit, and its Net Assets saw a rise of 1.99% compared to last year’s end.
Here is a link to what can only be described as historically impressive quarterly results. While the concept is simple, there is no predicting what businesses will be added to the mix. Given the provenance of the executives, the risk/reward scale seems to tilt to the latter.
Readen is an aggressive trader with a 52-week range of USD$0.02 to USD0.21. Not a bad run for a pinkie.
Lots more to this one. Lots.
Next? Pharmagreen
Pharmagreen Biotech, Inc., (OTCQB: PHBI) (“Pharmagreen” or the “Company”) provides the highest quality starter plantlets utilizing a proprietary tissue culture process, “Chibafreen,” to licensed cannabis cultivators and CBD / CBG hemp farmers.
Peter Wojcik, CEO of Pharmagreen, stated, “We are laser-focused on getting revenues started with the lowest CAPEX as soon as possible. We plan to create products based on the whole plant and fungi, thereby maximizing the beneficial and therapeutic effects, the same approach we use with cannabis. Once the micro cannabis license gets approved, we will add cannabis-based products, both stand-alone and combined with other ingredients, to target specific ailments and help people prevent illness first.”
Unique companies are always more interesting to write about. PHBI is such an endeavour and encompasses legs in the plant market, therapeutics and therapies and growth logistics that, by their nature, improve the revenues and lower the cost of customers. The word ‘Proxy’ once again rears its potentially good head.
Services attributed to Pharmagreen will include Good Manufacturing Practices (GMP) certification for its Tissue Culture facilities, Cold Storage of plantlets, and Nurseries. Pharmagreen future brand of products will focus on manufacturing and marketing Cannabis products for medical and recreational markets in Canada with an eye on international calls. (LinkedIn Page)
And now the big boy/person pink tease.
Tencent Holdings Ltd ADR (OTC:TCEHY) is a leading internet content & information business based in the US. It opened the day at $39.66 after a previous close of $39.59. During the day, the price has varied from a low of $39.45 to a high of $39.91. The latest price was $39.58 (25-minute delay). Tencent Holdings Ltd ADR is listed on the PINK and employs 116,213 staff.
Founded in 1998 with its headquarters in Shenzhen, China, Tencent’s guiding principle is to use technology for good. Our communication and social services connect more than one billion people worldwide, helping them keep in touch with friends and family, access transportation, pay for daily necessities, and even be entertained.
Tencent also publishes some of the world’s most popular video games and other high-quality digital content, enriching interactive entertainment experiences for people around the globe.
Tencent is not directly listed on US exchange. It’s listed as an ADR on the pink sheets exchange. ADRs are not the actual stock of a company. It’s a receipt type that represents an actual share. It stands for “American Depository Receipt.” Many international brand companies’ ADRs on the US exchanges are listed as ADRs. These companies do not directly participate in the US exchanges.
Impress your friends. From acorns…
Give Readen and Pharmagreen a stern look.
©2024 10xAlerts